<?xml version="1.0" encoding="UTF-8"?>
<p>This product contains two distinct but complementary mAbs that have shown broad efficacy 
 <italic>in vitro</italic> and 
 <italic>in vivo</italic> against different group 1 and group 2 influenza viruses. A phase 2a clinical trial (NCT02071914) was conducted to evaluate the efficacy and safety of CT-P27 in an influenza challenge model. The study concluded in July 2014, however no results were reported. Currently recruiting, a phase 2b clinical trial (NCT03511066) is aimed to evaluate the efficacy and safety of the mAbs combo in comparison to placebo in subjects with acute uncomplicated influenza A infection.
</p>
